Alterity Therapeutics (ATHE) has released an update.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alterity Therapeutics has announced that its Phase 2 clinical trial of ATH434 for early-stage multiple system atrophy (MSA) will continue as recommended by the independent Data Monitoring Committee, which found no safety concerns. The trial is expected to be completed by November 2024, with top-line data anticipated in January 2025. ATH434 is an oral agent aimed at inhibiting the aggregation of neurodegenerative proteins and has already shown promise in Phase 1 studies.
For further insights into ATHE stock, check out TipRanks’ Stock Analysis page.